Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 74

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 74
---
 a patent claim, but which,
    nonetheless, ultimately may be found to affect the validity or enforceability of a patent claim;

    ●
    there
    may be other patents issued to others that will affect our freedom to operate;

    ●
    if
    the patents are challenged, a court could determine that they are invalid or unenforceable;

    ●
    there
    might be a significant change in the law that governs patentability, validity and infringement of our licensed patents or any future
    patents we may own that adversely affects the scope of our patent rights;

    ●
    a
    court could determine that a competitor’s technology or product does not infringe our patents or any future patents we may
    own; and

    ●
    the
    patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations or could be subject to compulsory
    licensing. If we encounter delays in our development or clinical trials, the period of time during which we could market our potential
    products under patent protection would be reduced.

49

Our
competitors may be able to circumvent patents or future patents that we may own by developing similar or alternative technologies or
products in a non-infringing manner. Our competitors may seek to market generic or biosimilar versions of any approved products by submitting
abbreviated new applications or biosimilar biological product applications to the FDA in which our competitors claim that our licensed
patents or any future patents we may own are invalid, unenforceable or not infringed. Alternatively, our competitors may seek approval
to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend or
assert our patents or any future patents we may own, including by filing lawsuits alleging patent infringement. In any of these types
of proceedings, a court or other agency with jurisdiction may find our licensed patents or any future patents we may own invalid or unenforceable.
We may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. Even
if we own or in-license valid and enforceable patents, these patents still may not provide protection against competing products or processes
sufficient to achieve our business objectives.

The
issuance of a patent is not conclusive as to its inventorship, scope, ownership, priority, validity or enforceability. In this regard,
third parties may challenge our patents or any future patents we may own in